Pre Exposure Prophylaxis News and Research

RSS

Study examines parental concerns of their sexual and gender minority adolescents using PrEP

Since its approval in 2012, HIV pre-exposure prophylaxis, or PrEP, has shown promise in reducing HIV infection rates by preventing infection in high-risk HIV-negative people.

2 Mar 2023

Use of dapivirine vaginal ring during third trimester of pregnancy poses no safety concerns

A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.

20 Feb 2023

Doxycycline taken after sex does not prevent bacterial STIs among cisgender women

Researchers from the University of Washington (UW), Kenya Medical Research Institute (KEMRI), and Hennepin Healthcare Research Institute (HHRI) announced results at CROI from a clinical trial demonstrating that doxycycline taken after sex does not prevent bacterial sexually transmitted infections (STIs) – chlamydia or gonorrhea – among cisgender women.

20 Feb 2023

HIV prevention model in Zambian prisons may be extended to other criminal justice facilities

A recent study performed in Zambia by University of Maryland School of Medicine's Institute of Human Virology researchers found that high uptake of HIV preventative medicine, known as pre-exposure prophylaxis (PrEP), is possible in prison populations with adequate resources and support from the criminal justice health system.

16 Feb 2023

New formulation can provide up to six months of full protection against HIV

For people at high risk of contracting HIV, missing doses of their daily HIV prevention pills can have big consequences. In some cases, missing a pill can lead to lack of protection against the virus.

9 Feb 2023

Side-effects and costs are important issues for users of HIV pre-exposure prophylaxis, survey finds

A new survey finds that men who would be potential users of HIV pre-exposure prophylaxis (PrEP) medication prefer long-acting injections over pills, but rank side effects and costs as the most important issues for them in considering whether to take PrEP.

1 Feb 2023

A slight increase in Mpox cases across the globe, along with an increase in deaths

The WHO discusses genomic sequencing of the Mpox virus, in addition to providing public and clinical health links between HIV and Mpox.

24 Jan 2023

WHO’s 14th situation report for the multi-country outbreak of mpox overviews the clinical and public health links between HIV and mpox

In the present report, researchers reported the most recent findings of MPXV infections.

23 Jan 2023

Investigational vaccine regimen safe but did not provide protection against HIV acquisition

An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined.

18 Jan 2023

What are the characteristics of misdiagnosed human mpox cases?

In a recent study, researchers characterized overlooked cases of monkeypox (MPX).

21 Dec 2022

Medicaid expansion and increase in PrEP, antiretroviral treatment could result in decline of new HIV infections

Enacting Medicaid expansion in Texas and increasing the use of preventive and antiviral medications could result in a decline of new HIV infections among young Black gay, bisexual, and other men who have sex with men (MSM) in Houston, reports a study in the January issue of Medical Care. The journal is published in the Lippincott portfolio by Wolters Kluwer.

13 Dec 2022

Knowledge and attitudes to mpox among GBMSM in Australia

Researchers presented the results of a cross-sectional survey done in Australia between August and September 2022.

12 Dec 2022

Study on mpox epidemiology in New York during summer 2022

Researchers presented a summary of their experience of identifying, managing, and vaccinating monkeypox (MPX) virus (MPXV)-infected individuals in New York during the summer season of 2022.

30 Nov 2022

Zimbabwe's approval of long-acting drug could provide effective options for HIV prevention

Zimbabwe's approval of the long-acting cabotegravir (CAB-LA) for use by HIV-negative people to reduce the risk of getting HIV could pave the way for effective options for HIV prevention, experts say.

30 Nov 2022

Study shows no undetected monkeypox virus transmission before May 2022 in Rotterdam and Amsterdam

Researchers investigated whether undetected human monkeypox virus transmission occurred before Rotterdam and Amsterdam's first documented monkeypox cases.

23 Nov 2022

Immunological responses against monkeypox virus concerning the 2022 outbreak

A new study aimed to analyze the kinetics of the pox-specific T-cell induction, the inflammatory profile, and the inflammatory profile in human cases of the current monkeypox outbreak.

9 Nov 2022

UC researchers receive NIH grant to study how alcohol, fentanyl affect HIV medications

The United States has set a goal of reducing the number of new HIV infections by 75% by 2025 and by at least 90% by 2030, mirroring the United Nations' initiative to end the AIDS epidemic as a global health threat by 2030.

2 Nov 2022

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19).

28 Oct 2022

Antibody-mediated protection against symptomatic COVID achieved at low serum neutralizing titers

In a recent study posted to the medRxiv* preprint server, researchers in the United States assessed the efficiency of protection mediated by antibodies against symptomatic coronavirus disease 2019 (COVID-19) at low serum-neutralizing titers.

24 Oct 2022

French study reports growing evidence of sexual activity-linked transmission of monkeypox

In a new study, researchers described patients with monkeypox virus (MPXV) infection.

3 Oct 2022